Radiotherapeutic study shows low exposure to healthy organs
Radiopharmaceuticals company Oncoinvent has announced the publication of clinical dosimetry data for Radspherin in ovarian and colorectal cancer in the Journal of Nuclear Medicine. The publication reports results from nine patients enrolled in the dosimetry cohorts of the Phase I Radspherin studies, which… Read More